Citius Pharmaceuticals Stock to Reverse Split on Tuesday, November 26th (NASDAQ:CTXR)

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) are going to reverse split on Tuesday, November 26th. The 1-25 reverse split was announced on Friday, November 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, November 25th.

Citius Pharmaceuticals Stock Performance

Shares of CTXR stock opened at $0.13 on Friday. Citius Pharmaceuticals has a 52 week low of $0.11 and a 52 week high of $1.07. The stock has a market capitalization of $24.18 million, a PE ratio of -0.56 and a beta of 1.66. The stock’s fifty day moving average is $0.40 and its 200-day moving average is $0.58.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th.

Institutional Investors Weigh In On Citius Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Armistice Capital LLC acquired a new position in Citius Pharmaceuticals in the second quarter valued at approximately $5,928,000. BNP Paribas Financial Markets lifted its stake in shares of Citius Pharmaceuticals by 88.5% in the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after purchasing an additional 32,686 shares during the period. Vanguard Group Inc. boosted its position in shares of Citius Pharmaceuticals by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock worth $6,286,000 after purchasing an additional 104,889 shares during the last quarter. Arkadios Wealth Advisors grew its stake in shares of Citius Pharmaceuticals by 50.0% during the second quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company’s stock worth $88,000 after purchasing an additional 50,000 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new stake in Citius Pharmaceuticals in the second quarter valued at about $69,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.